CA2415083A1 - Anti-hiv and anti-tumor peptides and fragments of lysozyme - Google Patents

Anti-hiv and anti-tumor peptides and fragments of lysozyme Download PDF

Info

Publication number
CA2415083A1
CA2415083A1 CA002415083A CA2415083A CA2415083A1 CA 2415083 A1 CA2415083 A1 CA 2415083A1 CA 002415083 A CA002415083 A CA 002415083A CA 2415083 A CA2415083 A CA 2415083A CA 2415083 A1 CA2415083 A1 CA 2415083A1
Authority
CA
Canada
Prior art keywords
fragment
amino acid
seq
lysozyme
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002415083A
Other languages
English (en)
French (fr)
Inventor
Sylvia Lee-Huang
Philip L. Huang
Paul Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2415083A1 publication Critical patent/CA2415083A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002415083A 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme Abandoned CA2415083A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21670200P 2000-07-07 2000-07-07
US60/216,702 2000-07-07
PCT/US2001/021582 WO2002004011A1 (en) 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme

Publications (1)

Publication Number Publication Date
CA2415083A1 true CA2415083A1 (en) 2002-01-17

Family

ID=22808164

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002415083A Abandoned CA2415083A1 (en) 2000-07-07 2001-07-09 Anti-hiv and anti-tumor peptides and fragments of lysozyme

Country Status (8)

Country Link
US (1) US7838275B2 (enExample)
EP (1) EP1303291B1 (enExample)
JP (1) JP2004505616A (enExample)
AT (1) ATE375800T1 (enExample)
AU (1) AU2001278884A1 (enExample)
CA (1) CA2415083A1 (enExample)
DE (1) DE60130994T2 (enExample)
WO (1) WO2002004011A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003246119B2 (en) * 2002-06-28 2008-02-21 Fuso Pharmaceutical Industries, Ltd. Anti-HIV agent
ITMI20061950A1 (it) * 2006-10-11 2008-04-12 Therapicon Srl Effetto antimetastatico in condizioni patologiche delle cellule umane
US7846430B2 (en) * 2007-03-02 2010-12-07 Stefano Ferrari Composition and method for treating bovine papilloma virus in equine
JP5806434B1 (ja) 2014-02-21 2015-11-10 国立大学法人東京海洋大学 ノロウィルス不活化剤及びその製造方法、ノロウィルス不活化方法、ノロウィルス不活化用リゾチーム類の製造方法、ノロウィルス感染の予防薬又は治療薬、並びにノロウィルス不活化用皮膚外用剤
KR102232006B1 (ko) 2016-12-28 2021-03-25 디아이씨 가부시끼가이샤 분산체 및 그것을 사용한 잉크젯용 잉크 조성물, 광변환층, 및 액정 표시 소자
CN110438106B (zh) * 2019-08-06 2021-03-23 北京华韵国丰新材料科技有限公司 一种人工设计的纳米溶菌酶和纳米溶菌酶的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5583211A (en) * 1992-10-29 1996-12-10 Beckman Instruments, Inc. Surface activated organic polymers useful for location - specific attachment of nucleic acids, peptides, proteins and oligosaccharides
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
JPH06211692A (ja) * 1993-01-21 1994-08-02 Nippon Oil Co Ltd 免疫増強剤
WO1995009176A1 (en) * 1993-09-28 1995-04-06 Beckman Instruments, Inc. Biopolymer synthesis utilizing surface activated, organic polymers
AU3307497A (en) * 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
GB9907366D0 (en) * 1999-03-30 1999-05-26 Medical Res Council Method for expressing proteins

Also Published As

Publication number Publication date
EP1303291B1 (en) 2007-10-17
WO2002004011A1 (en) 2002-01-17
DE60130994T2 (de) 2008-07-24
DE60130994D1 (de) 2007-11-29
AU2001278884A1 (en) 2002-01-21
EP1303291A4 (en) 2005-04-06
ATE375800T1 (de) 2007-11-15
US20050008631A1 (en) 2005-01-13
EP1303291A1 (en) 2003-04-23
JP2004505616A (ja) 2004-02-26
US7838275B2 (en) 2010-11-23

Similar Documents

Publication Publication Date Title
KR102588702B1 (ko) 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
Upcroft et al. Drug resistance in Giardia intestinalis
US6645934B1 (en) Peptide with radio protective effect
US12252523B2 (en) Erythropoietin-derived peptides and methods of protecting cells from oxidative damage induced by reactive oxygen species
AU2022442074A9 (en) Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and use thereof
EA010200B1 (ru) Рекомбинантные тканезащитные цитокины и кодирующие их нуклеиновые кислоты для защиты, восстановления и усиления чувствительных клеток, тканей и органов
EP1718325B1 (en) Treatment of bacterial infections
WO1993020207A1 (en) Use of restriction endonucleases against viruses, including hiv
DE69332883T2 (de) Ptp-d unterklasse der protein tyrosin phosphatasen
CA2042569A1 (en) Stabilized fgf composition
US20090053200A1 (en) Method for retarding unhealth manifestations brought by ageing of human beings
EP0362209B1 (en) New synthetic bioactive compounds and method of producing bioactive effect
US5317009A (en) Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof
EP0569703A2 (en) Method of treating and preventing viral infections using HBNF and MK protein
US7838275B2 (en) Anti-HIV and anti-tumor peptides and fragments of lysozyme
DE69636052T2 (de) Mpl-liganden analoga
EP2538961B1 (en) Inhibition of necrosis
RU2404190C2 (ru) Деамидированный интерферон-бета
CA2327811A1 (en) Short peptides for treatment of neurological degenerative diseases
JPH03501742A (ja) 抗バクテリア・抗マラリア性ペプタイド
WO2021179214A1 (en) Methods for enhancing anti-apoptotic pathway to prevent DOX toxicity
US6652861B1 (en) Anti-HIV and anti-tumor peptides and truncated polypeptides of MAP30
EP0580782B1 (en) An anti-hiv protein, tap 29, from trichosanthes, dna coding therefor and therapeutic uses thereof
JP2007536382A (ja) 放射線保護におけるｆｇｆ−２０の予防的使用および治療的使用
NL2025294B1 (en) Antimicrobial peptide for treatment and controlling virus infections

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued